Posts

Showing posts with the label cetuximab

The cetuximab saga.

Weakly cetuximab.

10-4, 1016.

Meet the new boss, same as the old boss.

Tailoring indications.

TAVAwRECk.

Go platinum.

One door closes.

Riddle me this.

Doublet, doublet, toil and troublet.

So which interpretation is right?

Call me Ishmael.

More is less.

Antiangiogenic match-off.

EGFR there any updates in esophageal treatment?